For Regenkit®/ RegenPRP® products (PRP alone technology)
For its Regenkit®/RegenPRP® products (PRP alone technology), the United States Patent and Trademark Office (USPTO) has recently issued U.S. Patents No. 11,241,458 directed to (i) several types of sterilized, vacuum-sealed, separator tubes (therapeutic and aesthetic use) for preparing PRP comprising an anticoagulant and a thixotropic gel and (ii) methods for preparing therapeutic PRP comprising centrifuging once such tubes.
Further, in relation to its PRP-HA technologies, Regen Lab is also delighted to announce recently issued patents in Europe and Korea, respectively EP3223875B1 and KR102362722B1 directed to kits/devices/systems for the preparation of BMC/PRP with hyaluronic acid comprising two containers – the first one containing an anticoagulant, a thixotropic gel and a biomaterial, and the second one containing another biomaterial – the biomaterials being selected from hyaluronic acid, chitosan and/or silk protein, and further optional combinations with e.g. cell extracts and/or coagulation activators.
Regen Lab actively pursues patent protection and regulatory approval of its products so that physicians have peace of mind that they can offer continuous, consistent, safe and effective treatment for their patients without the fear of being restricted in their practice.
More information on RegenLab patent
